Menu
Close
Home
About ImmuneOnco
About Us
Core Team
Development Strategy
ESG Report
Scientific Technology and R&D
Technology Platform
Product Pipeline
Latest Development
Company News
Investor Relations
Information Disclosure
Presentations
Corporate Governance
Investor Calendar
IR Contact
Join Us
Contact Us
Global
CN
TC
Home
CN
TC
About ImmuneOnco
About Us
Core Team
Development Strategy
ESG Report
Scientific Technology and R&D
Technology Platform
Product Pipeline
Scientific News
Company News
Investor Relations
Information Disclosure
Corporate Governance
Investor Calendar
Presentation Materials
Stock Information
Analyst Coverage
IR Contact
Email Subscription Center
Join Us
Contact Us
>
×
Company News
Home
Company News
News detail
ImmuneOnco Biopharmaceuticals' IMM2520 project completes first subject dosing
2023-03-23
1278
Previous article：
ImmuneOnco Biopharmaceuticals IMM47, IMM2520 and IMM2510 invention patents were granted by the State Intellectual Property Office of China
Next article：
ImmuneOnco Biopharmaceuticals' IMM47, IMM40H, IMM2520, and IMM2902 projects debut at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Back
Hot recommendation
2026-04-23
ImmuneOnco’s Subcutaneous IMM2510S IND Application Accepted, Pioneering a New Era of Bispecific Drug Delivery
More
2026-04-22
ImmuneOnco Subsidiary ImmuneCare Biopharmaceuticals Completes Enrollment for IMC-003 MAD Study, Marking New Phase in PAH Drug Development
More
2026-03-30
ImmuneOnco Initiates Phase III Trial of Amouravfop Alfa (IMM0306) in Relapsed/Refractory Follicular Lymphoma
More
For more information
Please follow the official wechat public account
2023-03-23
1278
